By Jake King
Shares of Questcor Pharmaceuticals (QCOR) have started to rise to more realistic valuations in the new year (as PropThink expected), breaking $31 dollars on Tuesday as the market gets comfortable with Acthar's profit-generating prospects and the company's fundamentals. PropThink covered Questcor extensively last year and suggested that fair value for shares of the H.P. Acthar maker was in the high $30 or $40 range. Bears have battered the company for Acthar's premium pricing and potential reimbursement pressures, but the vast majority of payers continue to acknowledge Acthar as a real last-ditch treatment for patients with serious medical conditions. In fact, just last week, BlueCross BlueShield of Illinois updated its policy on Acthar, deeming the product necessary for the treatment of infantile spasms and in other indications where there are medical contraindications or intolerance to first-line treatments (typically corticosteroids).
QCOR proved in 3Q12 that reimbursement for Acthar remained strong, beating estimates on both the top and bottom line and sending the shorts packing. Since then, the company has remained fundamentally sound, and a company filing from early January expounded on a number of business milestones indicating that growth was likely to continue:
- Questcor stated that 4Q12 held "record vial shipments of H.P. Acthar Gel." Based on discussions with industry sources, we believe that the strong vial shipments were consistent throughout 4Q, and continue to indicate the trend.
- Patients "continued to have access to Acthar through commercial insurance, Medicare, Medicaid and other government programs." While the shorts continue to harp on this facet of the QCOR story, it's becoming less and less of a concern, and 4Q results could support this claim.
- Questcor is expanding its pilot rheumatology sales force, which PropThink opined was likely as the product proved out in the real-world. Questcor is expanding its rheumatology sales force from the initial pilot force of 12 to 50. This not only indicates a larger market, but greater demand for Acthar.
- The company discussed briefly the closing of its BioVectra acquisition. Revenues for the third-party Acthar manufacturer, which Questcor now fully owns, were ~$20M in 2012, and the CEO of BioVectra had stated prior to being acquired that he expected revenues of more than $40M in 2013. The cost savings - vertical integration - and long-term revenue potential are expected to be a key contributor to earnings power and growth.
In addition, recall that Acthar's Medicaid rebate was cut from 100% to 23.1% last September. The company was selling approximately $14M worth of Acthar to Medicaid patients quarterly, in which the company was absorbing 100% of the costs, but now is adding ~$10M (77% of those sales) to operating profit per quarter. This calculation does not factor in growth, and given the profitability on these sales, we expect the company to promote more heavily to the Medicaid segment going forward. Like the BioVectra acquisition, the Medicaid rebate benefit now significantly adds to earnings power and growth prospects.
Questcor will report 4Q12 and full-year earnings next Tuesday, and we wouldn't be surprised to see the strong growth trends show up in the earnings results. The "record" number of vials shipped in 4Q, as indicated by the company, is not something the shorts are going to want to face next week, hence, we would expect QCOR to work higher into earnings. Should sales of Acthar demonstrate that the product is continuing to gain traction, analyst price targets could rise in kind, with the stock potentially getting back to historic highs. Questcor's Acthar business is firing on all cylinders, fundamentals are looking strong (as are technicals) and perhaps most importantly, we're starting to see the heavy short interest moving on; based on 3Q12 results alone, we believe QCOR is fairly valued in the high $30's. Strong 4Q results could indicate that the stock could power through this level.
Disclosure: I am long QCOR. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
Additional disclosure: PropThink is a team of editors, analysts, and writers. This article was written by Jake King. We did not receive compensation for this article, and we have no business relationship with any company whose stock is mentioned in this article. Use of PropThink’s research is at your own risk. You should do your own research and due diligence before making any investment decision with respect to securities covered herein.You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. Our full disclaimer is available at www.propthink.com/disclaimer.